Eaton Vance Management Cytosorbents Corp Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
Shares
4 transactions
Others Institutions Holding CTSO
# of Institutions
55Shares Held
16.9MCall Options Held
10.1KPut Options Held
500-
Avenir Corp Washington, DC2.97MShares$3.53 Million0.21% of portfolio
-
Skylands Capital, LLC2.84MShares$3.38 Million0.3% of portfolio
-
Granahan Investment Management, LLC Waltham, MA2.66MShares$3.17 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$2.32 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.54MShares$1.83 Million0.0% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $51.9M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...